160 related articles for article (PubMed ID: 24890689)
1. Bimodal mortality dynamics for uveal melanoma: a cue for metastasis development traits?
Demicheli R; Fornili M; Biganzoli E
BMC Cancer; 2014 Jun; 14():392. PubMed ID: 24890689
[TBL] [Abstract][Full Text] [Related]
2. Delayed systemic recurrence of uveal melanoma.
Kolandjian NA; Wei C; Patel SP; Richard JL; Dett T; Papadopoulos NE; Bedikian AY
Am J Clin Oncol; 2013 Oct; 36(5):443-9. PubMed ID: 22706174
[TBL] [Abstract][Full Text] [Related]
3. The Results of Stricter Inclusion Criteria in an Immunomagnetic Detection Study of Micrometastatic Cells in Bone Marrow of Uveal Melanoma Patients - Relevance for Dormancy.
Eide N; Faye RS; Høifødt HK; Sandvik L; Qvale GA; Faber R; Jebsen P; Kvalheim G; Fodstad Ø
Pathol Oncol Res; 2019 Jan; 25(1):255-262. PubMed ID: 29098521
[TBL] [Abstract][Full Text] [Related]
4. Long-term Risk of Melanoma-Related Mortality for Patients With Uveal Melanoma Treated With Proton Beam Therapy.
Lane AM; Kim IK; Gragoudas ES
JAMA Ophthalmol; 2015 Jul; 133(7):792-6. PubMed ID: 25905597
[TBL] [Abstract][Full Text] [Related]
5. Survival from uveal melanoma in Western Australia 1981-2005.
Chew AL; Spilsbury K; Isaacs TW
Clin Exp Ophthalmol; 2015 Jul; 43(5):422-8. PubMed ID: 25556534
[TBL] [Abstract][Full Text] [Related]
6. Very long-term prognosis of patients with malignant uveal melanoma.
Kujala E; Mäkitie T; Kivelä T
Invest Ophthalmol Vis Sci; 2003 Nov; 44(11):4651-9. PubMed ID: 14578381
[TBL] [Abstract][Full Text] [Related]
7. Mortality after uveal and conjunctival melanoma: which tumour is more deadly?
Kujala E; Tuomaala S; Eskelin S; Kivelä T
Acta Ophthalmol; 2009 Mar; 87(2):149-53. PubMed ID: 18937804
[TBL] [Abstract][Full Text] [Related]
8. Post-brachytherapy initial tumour regression rate correlates with metastatic spread in posterior uveal melanoma.
Kaiserman I; Anteby I; Chowers I; Blumenthal EZ; Kliers I; Pe'er J
Br J Ophthalmol; 2004 Jul; 88(7):892-5. PubMed ID: 15205232
[TBL] [Abstract][Full Text] [Related]
9. Recurrence dynamics does not depend on the recurrence site.
Demicheli R; Biganzoli E; Boracchi P; Greco M; Retsky MW
Breast Cancer Res; 2008; 10(5):R83. PubMed ID: 18844974
[TBL] [Abstract][Full Text] [Related]
10. Prognostic implications of monosomy 3 in uveal melanoma.
Prescher G; Bornfeld N; Hirche H; Horsthemke B; Jöckel KH; Becher R
Lancet; 1996 May; 347(9010):1222-5. PubMed ID: 8622452
[TBL] [Abstract][Full Text] [Related]
11. Prognostication of metastatic death in uveal melanoma patients: A Markov multi-state model.
Eleuteri A; Taktak AFG; Coupland SE; Heimann H; Kalirai H; Damato B
Comput Biol Med; 2018 Nov; 102():151-156. PubMed ID: 30278339
[TBL] [Abstract][Full Text] [Related]
12. Local recurrence after uveal melanoma proton beam therapy: recurrence types and prognostic consequences.
Caujolle JP; Paoli V; Chamorey E; Maschi C; Baillif S; Herault J; Gastaud P; Hannoun-Levi JM
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1218-24. PubMed ID: 23177670
[TBL] [Abstract][Full Text] [Related]
13. International Validation of the American Joint Committee on Cancer's 7th Edition Classification of Uveal Melanoma.
AJCC Ophthalmic Oncology Task Force
JAMA Ophthalmol; 2015 Apr; 133(4):376-83. PubMed ID: 25555246
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Metastatic Risk after Biopsy of Posterior Uveal Melanoma.
Bagger M; Smidt-Nielsen I; Andersen MK; Jensen PK; Heegaard S; Andersen KK; Friis S; Kiilgaard JF
Ophthalmology; 2018 Dec; 125(12):1969-1976. PubMed ID: 29705056
[TBL] [Abstract][Full Text] [Related]
15. Forty-year prognosis after plaque brachytherapy of uveal melanoma.
Stålhammar G
Sci Rep; 2020 Jul; 10(1):11297. PubMed ID: 32647177
[TBL] [Abstract][Full Text] [Related]
16. No differences in outcome between radical surgical treatment (enucleation) and stereotactic radiosurgery in patients with posterior uveal melanoma.
Furdova A; Slezak P; Chorvath M; Waczulikova I; Sramka M; Kralik G
Neoplasma; 2010; 57(4):377-81. PubMed ID: 20429631
[TBL] [Abstract][Full Text] [Related]
17. Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors.
Bedikian AY; Legha SS; Mavligit G; Carrasco CH; Khorana S; Plager C; Papadopoulos N; Benjamin RS
Cancer; 1995 Nov; 76(9):1665-70. PubMed ID: 8635073
[TBL] [Abstract][Full Text] [Related]
18. Reduced expression of autotaxin predicts survival in uveal melanoma.
Singh AD; Sisley K; Xu Y; Li J; Faber P; Plummer SJ; Mudhar HS; Rennie IG; Kessler PM; Casey G; Williams BG
Br J Ophthalmol; 2007 Oct; 91(10):1385-92. PubMed ID: 17475713
[TBL] [Abstract][Full Text] [Related]
19. ADAM 10 expression in primary uveal melanoma as prognostic factor for risk of metastasis.
Caltabiano R; Puzzo L; Barresi V; Ieni A; Loreto C; Musumeci G; Castrogiovanni P; Ragusa M; Foti P; Russo A; Longo A; Reibaldi M
Pathol Res Pract; 2016 Nov; 212(11):980-987. PubMed ID: 27546281
[TBL] [Abstract][Full Text] [Related]
20. Clinical predictors of survival in metastatic uveal melanoma.
Lorenzo D; Piulats JM; Ochoa M; Arias L; Gutiérrez C; Català J; Cobos E; Garcia-Bru P; Dias B; Padrón-Pérez N; Caminal JM
Jpn J Ophthalmol; 2019 Mar; 63(2):197-209. PubMed ID: 30796549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
